Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

HLA-DQA1∗05 Genotype and Immunogenicity to Tumor Necrosis Factor-α Antagonists: A Systematic Review and Meta-analysis
Virginia Solitano, Antonio Facciorusso, Dermot McGovern, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 21, Iss. 12, pp. 3019-3029.e5
Open Access | Times Cited: 24

Showing 24 citing articles:

Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study
Neil Chanchlani, Simeng Lin, Claire Bewshea, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 6, pp. 521-538
Open Access | Times Cited: 33
A Narrative Review of Cytokine Networks: Pathophysiological and Therapeutic Implications for Inflammatory Bowel Disease Pathogenesis
Marek Vébr, Renata Pomahačová, Josef Sýkora, et al.
Biomedicines (2023) Vol. 11, Iss. 12, pp. 3229-3229
Open Access | Times Cited: 23
Review article: Measuring disease severity in inflammatory bowel disease – Beyond treat to target
Akhilesh Swaminathan, Andrew S. Day, Miles Sparrow, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 9, pp. 1176-1199
Open Access | Times Cited: 10
Impact of HLA-DQA1*05 Genotype in Immunogenicity and Failure to Treatment with Tumour Necrosis Factor-alpha Antagonists in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Leticia Rodríguez-Alcolado, Elena Grueso-Navarro, Ángel Arias, et al.
Journal of Crohn s and Colitis (2024) Vol. 18, Iss. 7, pp. 1034-1052
Closed Access | Times Cited: 6
Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Dahham Alsoud, Dirk Jan A. R. Moes, Zhigang Wang, et al.
Therapeutic Drug Monitoring (2024) Vol. 46, Iss. 3, pp. 291-308
Closed Access | Times Cited: 5
Involvement of HLADQA1*05 in Patients with Inflammatory Bowel Disease Treated with Anti-TNF Drugs
Anna Pau, Ilaria Galliano, Elisa Barnini, et al.
Medicina (2025) Vol. 61, Iss. 1, pp. 102-102
Open Access
Establishment and internal validation of a model to predict the efficacy of Adalimumab in Crohn’s disease
Fang Wang, He Zhou, Yujie Zhang, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Age as a Predictor of Serum Tumor Necrosis Factor Antagonist Drug and Antidrug Antibody Concentrations in Inflammatory Bowel Disease—A Nationwide Cohort Study
Mohammad Shehab, Fatema Alrashed
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1057-1057
Open Access
The role of immunogenicity in optimizing biological therapies for inflammatory bowel disease
Konika Sharma, Brad W. deSilva, Stephen B. Hanauer
Expert Review of Gastroenterology & Hepatology (2025)
Closed Access
Causal associations between autoimmune diseases and sarcopenia-related traits: a bi-directional Mendelian randomization study
Chunlan Chen, Ying He
Frontiers in Genetics (2024) Vol. 15
Open Access | Times Cited: 2
Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations
Ole Haagen Nielsen, Alexander Hammerhøj, Mark Ainsworth, et al.
Drugs (2024)
Closed Access | Times Cited: 2
Withdrawal of Immunomodulators or TNF Antagonists in Patients With Inflammatory Bowel Diseases in Remission on Combination Therapy: A Systematic Review and Meta-analysis
David J. Katibian, Virginia Solitano, D. Brent Polk, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 22, Iss. 1, pp. 22-33.e6
Closed Access | Times Cited: 7
Carriage of the HLA-DQA1⋆05 haplotype is associated with a higher risk of infratherapeutic drug concentration and higher immunogenicity in patients undergoing treatment with anti-TNF for inflammatory bowel disease
Pilar Navajas Hernández, Samer Mouhtar El Hálabi, Ana Caridad González Parra, et al.
Therapeutic Advances in Gastroenterology (2024) Vol. 17
Open Access | Times Cited: 1
Advancements in the management of pediatric inflammatory bowel disease
Jonathan O'Donnell, Sonia Thomas, Eric I. Benchimol
Expert Review of Gastroenterology & Hepatology (2024)
Closed Access | Times Cited: 1
Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-α
Elizabeth Spencer, Marla C. Dubinsky, Michael A. Kamm, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Challenges in IBD Research 2024: Pragmatic Clinical Research
Jessica R. Allegretti, Liliana Bordeianou, Oriana M. Damas, et al.
Inflammatory Bowel Diseases (2024) Vol. 30, Iss. Supplement_2, pp. S55-S66
Open Access | Times Cited: 1
Arthritis complicating inflammatory bowel disease— the future is now
Kaiyang Song, Jack Satsangi, Laura C. Coates
The Lancet Rheumatology (2024) Vol. 6, Iss. 11, pp. e805-e810
Closed Access | Times Cited: 1
Influence of HLA-DQA1*05 on the loss of response to anti-TNF treatment in inflammatory bowel disease. Spanish cohort of real clinical practice
Jorge Pérez Pérez, Jaime Escobar Ortiz, Anabel Franco‐Moreno, et al.
Gastroenterología y Hepatología (2024) Vol. 47, Iss. 8, pp. 869-871
Closed Access
Ustekinumab as alternative for anti-TNFs in HLA-DQA1*05-positive Crohn’s disease
Robert van den Heuvel
(2024)
Closed Access
Influence of HLA-DQA1*05 on the loss of response to anti-TNF treatment in inflammatory bowel disease. Spanish cohort of real clinical practice
Jorge Pérez Pérez, Jaime Escobar Ortiz, Anabel Franco‐Moreno, et al.
Gastroenterología y Hepatología (English Edition) (2024) Vol. 47, Iss. 8, pp. 869-871
Closed Access
Does HLA‐DQA1*05 carriage have a greater impact on the outcome of infliximab therapy for isolated small‐bowel Crohn's disease?
Juan Wu, Nannan Zhu, Jing Hu, et al.
International Journal of Immunogenetics (2024) Vol. 51, Iss. 6, pp. 380-387
Closed Access
HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn’s Disease
Jeremy Adler, Joseph A. Galanko, Rana Ammoury, et al.
The American Journal of Gastroenterology (2024)
Closed Access
Establishment and Internal Validation of a Model to Predict the Efficacy of Adalimumab in Crohn's Disease
Fang Wang, Tong Wu, He Zhou, et al.
Research Square (Research Square) (2024)
Open Access
Impact Of Hladqa1*05 And Hladqa1*03 On Safety And Loss Of Response To Anti-Tnf In Patients With Inflammatory Bowel Disease
Julia López de la Cruz, Fernando Gomollón, Javier Louro, et al.
Journal of Crohn s and Colitis (2024)
Closed Access
Can Proactive Therapeutic Drug Monitoring Overcome Pharmacogenomic-Associated Immunogenicity to Anti-Tumor Necrosis Factor Agents?
Munique Kurtz de Mello, Natália Sousa Freitas Queiroz, Konstantinos Papamichael
Clinical Gastroenterology and Hepatology (2023) Vol. 22, Iss. 1, pp. 200-201
Open Access
Page 1

Scroll to top